glp-1 cardiovascular outcomes trial results august 2025 The Big of a drug (Wegovy) to Reduce Major Events GLP-1 trends 2025: real-world data,

GI side effects: - Nausea: reported at rates comparable to other GLP-1/GIP drugs - Vomiting: 26% of VK2735-treated subjects vs 10% on placebo higher than most competitors - Diarrhea and constipation: within the expected range for this drug class The vomiting rate is the main concern

While promising results have been observed in animal studies and anecdotal reports, comprehensive clinical trials are necessary to establish its safety and efficacy

An MD or DO performs a clinical evaluation, orders baseline labs, documents an indication, and writes a prescription

Researchers are finding that GLP-1 agonists influence multiple pathways involved in inflammation, cardiovascular health, mood, motivation and rewardbenefits that appear to extend beyond the downstream effects of weight loss alone